


CLAIMS

- Sub B1
1. A seamed soft capsule formulation in which a solution of a dihydrobenzofuran derivative represented by general formula (1):



wherein R₁ represents a hydrogen atom or an acyl group; R₂ represents a hydrogen atom or a lower alkyl group; and R₃ and R₄, which may be identical or different, represent a hydrogen atom or a substituted or unsubstituted alkyl, alkenyl, alkynyl or aryl group, or probucol in a fat and oil is filled into a seamed soft capsule.

- furan
or
Probucol?
↓
Panavir
2. The formulation of Claim 1 wherein said compound represented by general formula (1) is 4,6-di-tert-butyl-2,2-di-n-pentyl-5-hydroxy-2,3-dihydrobenzofuran.

3. The formulation of Claim 1 or 2 wherein said fat and oil is a vegetable oil.

4. The formulation of Claim 3 wherein said vegetable oil contains an unsaturated fatty acid as a major constituent.

5. The formulation of Claim 4 wherein said vegetable oil is soybean oil.

- Sub B1
6. The formulation of Claim 1 or 2 wherein shell of said soft capsule contains gelatin and concentrated glycerin.

7. The formulation of Claim 1 or 2 wherein shell of

Sub B cont
said soft capsule contains sorbitol.

8. The formulation of Claim 6 wherein said shell of said soft capsule further contains sorbitol.

9. The formulation of Claim 8 wherein said soft capsule contains 15-50 parts by weight of concentrated glycerin per 100 parts by weight of gelatin.

10. The formulation of Claim 9 wherein said soft capsule contains 20-45 parts by weight of concentrated glycerin per 100 parts by weight of gelatin.

11. The formulation of Claim 8 wherein said shell of said soft capsule contains 5-15 parts by weight of sorbitol per 100 parts by weight of gelatin.

12. The formulation of Claim 11 wherein said sorbitol is present in said shell at a ratio of 7-10 parts by weight of sorbitol to 100 parts by weight of gelatin.

13. The formulation of Claim 1 or 2 wherein a thickness as formed of shell of said soft capsule is from 28×10^{-3} inch (71×10^{-2} mm) to 40×10^{-3} inch (100×10^{-2} mm).

14. The formulation of Claim 13 wherein said thickness is from 30×10^{-3} inch (76×10^{-2} mm) to 35×10^{-3} in (89×10^{-2} mm).

15. A seamed soft capsule formulation containing 4,6-di-tert-butyl-2,2-di-n-pentyl-5-hydroxy-2,3-dihydrobenzofuran.

Sub B cont
16. A method for treating an arteriosclerosis comprising administering said seamed soft capsule formulation of Claim 1 or 2 to a patient suffering from

Sub
B. cont

said arteriosclerosis.

17. A method for treating an arteriosclerosis comprising administering said seamed soft capsule formulation of Claim 15 to a patient suffering from said arteriosclerosis.

09914066-082301